MOLECULAR PARTNERS AG
MOLNMolecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.
Drugs in Pipeline
26
Phase 3 Programs
7
Upcoming Catalysts
2
Next Catalyst
Jun 1, 2026
2dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Short regimen of benznidazole Phase 3 Est. Readout
Primary completion for Short regimen of benznidazole trial (NCT04897516) in Chagas Disease
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Short regimen of benznidazole
Chagas Disease
Florbetaben (BAY94-9172)
Down Syndrome
[18F]PI-2620
Alzheimer Disease
mycophenolate mofetil
Familial Lipoprotein Lipase Deficiency
[18F]florbetaben
Cardiac Amyloidosis
Inactivated SARS-CoV-2 vaccine (Vero cell)
COVID-19 Virus Infection
11C-choline Injection
Metastatic Prostate Cancer
ATL-001 (Ciclopirox oral solution)
Congenital Erythropoietic Porphyria (CEP)
PMD-026
Metastatic Breast Cancer
AMT-101 (oral)
Ulcerative Colitis
[F 18]HX4
Head and Neck Cancer
AMT-101 (oral)-Dose A
Pouchitis
[F-18] FMISO
Head and Neck Cancer
[F-18]RGD-K5
Metastatic Breast Cancer
Racotumomab
Neuroblastoma
Desmopressin
Colorectal Cancer
PTR-01
Recessive Dystrophic Epidermolysis Bullosa
CIGB300
Squamous Cell Carcinoma of the Cervix
MP0250
Neoplasms
Cannabidiol 100 mg/ml
Parkinson Disease
ensovibep
Covid19
MP0250 plus BOR+DEX
Multiple Myeloma in Relapse
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1
Leukemia
[212Pb]Pb-MP0712
Large Cell Neuroendocrine Carcinoma
4D-310
Fabry Disease
99mTc-glucarate solution
Acute Coronary Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Short regimen of benznidazole | Phase 3 | Chagas Disease | - | - |
Florbetaben (BAY94-9172) | Phase 3 | Down Syndrome | - | - |
[18F]PI-2620 | Phase 3 | Alzheimer Disease | - | - |
mycophenolate mofetil | Phase 3 | Familial Lipoprotein Lipase Deficiency | - | - |
[18F]florbetaben | Phase 3 | Cardiac Amyloidosis | - | - |
Inactivated SARS-CoV-2 vaccine (Vero cell) | Phase 3 | COVID-19 Virus Infection | - | - |
11C-choline Injection | Phase 3 | Metastatic Prostate Cancer | - | - |
ATL-001 (Ciclopirox oral solution) | Phase 2 | Congenital Erythropoietic Porphyria (CEP) | - | - |
PMD-026 | Phase 2 | Metastatic Breast Cancer | - | - |
AMT-101 (oral) | Phase 2 | Ulcerative Colitis | - | - |
[F 18]HX4 | Phase 2 | Head and Neck Cancer | - | - |
AMT-101 (oral)-Dose A | Phase 2 | Pouchitis | - | - |
[F-18] FMISO | Phase 2 | Head and Neck Cancer | - | - |
[F-18]RGD-K5 | Phase 2 | Metastatic Breast Cancer | - | - |
Racotumomab | Phase 2 | Neuroblastoma | - | - |
Desmopressin | Phase 2 | Colorectal Cancer | - | - |
PTR-01 | Phase 2 | Recessive Dystrophic Epidermolysis Bullosa | - | - |
CIGB300 | Phase 2 | Squamous Cell Carcinoma of the Cervix | - | - |
MP0250 | Phase 2 | Neoplasms | - | - |
Cannabidiol 100 mg/ml | Phase 2 | Parkinson Disease | - | - |
ensovibep | Phase 2 | Covid19 | - | - |
MP0250 plus BOR+DEX | Phase 2 | Multiple Myeloma in Relapse | - | - |
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 | Phase 2 | Leukemia | - | - |
[212Pb]Pb-MP0712 | Phase 2 | Large Cell Neuroendocrine Carcinoma | - | - |
4D-310 | Phase 2 | Fabry Disease | - | - |
99mTc-glucarate solution | Phase 2 | Acute Coronary Syndrome | - | - |